Servi­er, Pfiz­er get FDA OK to start US test­ing of an off-the-shelf CAR-T from Cel­lec­tis

Just a month af­ter the FDA signed off on the first US study for an off-the-shelf CAR-T ther­a­py from Cel­lec­tis $CLLS, its part­ners at Servi­er and Pfiz­er $PFE now have a green light to be­gin treat­ing pa­tients in the US with UCART19, an al­lo­gene­ic ther­a­py for acute lym­phoblas­tic leukemia.

Servi­er and Pfiz­er have a deal to co-de­vel­op UCART19, ini­tial­ly launch­ing their Phase I CALM tri­al in the UK last sum­mer in CD19-pos­i­tive B-cell ALL. Now they can be­gin treat­ing pa­tients at a num­ber of US cen­ters, in­clud­ing the MD An­der­son Can­cer Cen­ter in Hous­ton, a hotbed of can­cer drug re­search.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA